BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 26123543)

  • 1. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer.
    Cheung SY; Boey YJ; Koh VC; Thike AA; Lim JC; Iqbal J; Tan PH
    Breast Cancer Res Treat; 2015 Aug; 152(3):489-98. PubMed ID: 26123543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of epithelial-mesenchymal transition-related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome.
    Jang MH; Kim HJ; Kim EJ; Chung YR; Park SY
    Hum Pathol; 2015 Sep; 46(9):1267-74. PubMed ID: 26170011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
    Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
    Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast.
    Oon ML; Thike AA; Tan SY; Tan PH
    Breast Cancer Res Treat; 2015 Feb; 150(1):31-41. PubMed ID: 25677743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
    Kim S; Lee J; Jeon M; Nam SJ; Lee JE
    Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MAGE-A is frequently expressed in triple negative breast cancer and associated with epithelial-mesenchymal transition.
    Wang H; Sang M; Geng C; Liu F; Gu L; Shan B
    Neoplasma; 2016; 63(1):44-56. PubMed ID: 26639233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical study of the epithelial-mesenchymal transition phenotype in cancer of unknown primary: incidence, correlations and prognostic utility.
    Stoyianni A; Goussia A; Pentheroudakis G; Siozopoulou V; Ioachim E; Krikelis D; Golfinopoulos V; Cervantes A; Bobos M; Fotsis T; Bellou S; Fountzilas G; Malamou-Mitsi V; Pavlidis N
    Anticancer Res; 2012 Apr; 32(4):1273-81. PubMed ID: 22493359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.
    Ipekci T; Ozden F; Unal B; Saygin C; Uzunaslan D; Ates E
    Pathol Oncol Res; 2015 Sep; 21(4):1209-16. PubMed ID: 26037169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular biomarkers for prediction of response to treatment and survival in triple negative breast cancer patients from Egypt.
    Bahnassy A; Mohanad M; Ismail MF; Shaarawy S; El-Bastawisy A; Zekri AR
    Exp Mol Pathol; 2015 Oct; 99(2):303-11. PubMed ID: 26232605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of epithelial-mesenchymal transition and cancer stem cell-like phenotypes has independent prognostic value in gastric cancer.
    Ryu HS; Park DJ; Kim HH; Kim WH; Lee HS
    Hum Pathol; 2012 Apr; 43(4):520-8. PubMed ID: 22018628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of RAB1B promotes triple-negative breast cancer metastasis by activating TGF-β/SMAD signaling.
    Jiang HL; Sun HF; Gao SP; Li LD; Hu X; Wu J; Jin W
    Oncotarget; 2015 Jun; 6(18):16352-65. PubMed ID: 25970785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epithelial-to-mesenchymal transition in metaplastic breast carcinomas with chondroid differentiation: expression of the E-cadherin repressor Snail.
    Gwin K; Buell-Gutbrod R; Tretiakova M; Montag A
    Appl Immunohistochem Mol Morphol; 2010 Dec; 18(6):526-31. PubMed ID: 20697265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TWIST1 and SNAI1 as markers of poor prognosis in human colorectal cancer are associated with the expression of ALDH1 and TGF-β1.
    Kim YH; Kim G; Kwon CI; Kim JW; Park PW; Hahm KB
    Oncol Rep; 2014 Mar; 31(3):1380-8. PubMed ID: 24402192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
    Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
    Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors.
    Galván JA; Astudillo A; Vallina A; Fonseca PJ; Gómez-Izquierdo L; García-Carbonero R; González MV
    Am J Clin Pathol; 2013 Jul; 140(1):61-72. PubMed ID: 23765535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression patterns of claudins in patients with triple-negative breast cancer are associated with nodal metastasis and worse outcome.
    Katayama A; Handa T; Komatsu K; Togo M; Horiguchi J; Nishiyama M; Oyama T
    Pathol Int; 2017 Aug; 67(8):404-413. PubMed ID: 28699235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarcomatoid renal cell carcinoma is an example of epithelial--mesenchymal transition.
    Conant JL; Peng Z; Evans MF; Naud S; Cooper K
    J Clin Pathol; 2011 Dec; 64(12):1088-92. PubMed ID: 22003062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implications of the Notch1-Snail/Slug-epithelial to mesenchymal transition axis for lymph node metastasis in infiltrating ductal carcinoma.
    Cao YW; Wan GX; Sun JP; Cui XB; Hu JM; Liang WH; Zheng YQ; Li WQ; Li F
    Kaohsiung J Med Sci; 2015 Feb; 31(2):70-6. PubMed ID: 25645984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of microRNA-9 and microRNA-155 expression in triple-negative breast cancer.
    Jang MH; Kim HJ; Gwak JM; Chung YR; Park SY
    Hum Pathol; 2017 Oct; 68():69-78. PubMed ID: 28882698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epithelial to mesenchymal transition markers are associated with an increased metastatic risk in primary cutaneous squamous cell carcinomas but are attenuated in lymph node metastases.
    Toll A; Masferrer E; Hernández-Ruiz ME; Ferrandiz-Pulido C; Yébenes M; Jaka A; Tuneu A; Jucglà A; Gimeno J; Baró T; Casado B; Gandarillas A; Costa I; Mojal S; Peña R; de Herreros AG; García-Patos V; Pujol RM; Hernández-Muñoz I
    J Dermatol Sci; 2013 Nov; 72(2):93-102. PubMed ID: 23928229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.